ClinicalTrials.gg

Program

cemsidomide

Also written as “Cemsidomide”.

Its studies are mostly in Multiple Myeloma, led by C4 Therapeutics.

Furthest: phase 2, since Dec 9, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
C4 Therapeutics33 open or runningphase 2since Dec 9, 2025Feb 12, 2021Dec 2028phase 1 · NCT07280013

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04756726 · 224 enrolled · United States
  2. Dec 1, 2025Phase 1 study in Multiple MyelomaNCT07280013 · 60 planned · United States
  3. Dec 9, 2025Phase 2 study in Multiple MyelomaPhase 2 reachedNCT07284758 · 100 planned · United States, France, Italy and more

Ahead

  1. Dec 2028Primary completion: phase 1 study in Multiple MyelomaNCT07280013
  2. Mar 2030Primary completion: phase 2 study in Multiple MyelomaNCT07284758

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07284758Multiple Myeloma · United States, France, Italy and more2RecruitingMar 2030100
NCT07280013Multiple Myeloma · United States1RecruitingDec 202860
NCT04756726Multiple Myeloma · United States1Active, not recruitingSep 30, 2026224

How it is read

Names in the registry

  • “Cemsidomide”, 2 entries
  • “cemsidomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.